In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. It operates through the Active Ingredient and Biopharmaceutical segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback